Immunologic aspects of gynecologic cancer.
Di Saia
P J
PJ
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000951:Antigens, Neoplasm / Q000008:administration & dosage; D001500:BCG Vaccine / Q000627:therapeutic use; D002272:Carcinoembryonic Antigen; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D005260:Female; D005833:Genital Neoplasms, Female / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology* / Q000628:therapy*; D006801:Humans; D007111:Immunity, Cellular; D007116:Immunization, Passive; D007167:Immunotherapy; D007370:Interferon Type I / Q000627:therapeutic use; D007694:Killer Cells, Natural / Q000276:immunology; D011425:Propionibacterium acnes; D014165:Transfer Factor / Q000627:therapeutic use; D014612:Vaccines; D000509:alpha-Fetoproteins
D000276:Adjuvants, Immunologic; D000951:Antigens, Neoplasm; D001500:BCG Vaccine; D002272:Carcinoembryonic Antigen; D007370:Interferon Type I; D014165:Transfer Factor; D014612:Vaccines; D000509:alpha-Fetoproteins